Intrinsa fails to impress FDA advisory panel (original) (raw)

• Perspective
• Published: 17 March 2005

Perspectives

International Journal of Impotence Research volume 17, pages 283–284 (2005)Cite this article

• 1420 Accesses
• 13 Citations
• 18 Altmetric
• Metrics details

Abstract

Editor's Note: Female sexual dysfunction (FSD) as a discipline of medicine is not fully recognized by many authorities. Definitions are controversial and data are lacking, yet the public clamors for treatment. The lay press has capitalized on this provocative women's issue, seizing on the public's insatiable desire for new, potentially ‘sexy’ therapeutic options in this area. Thus, the time was ripe for a potential FSD drug. The sexual medicine community watched with interest as the Food and Drug Administration (FDA) considered the Proctor & Gamble new drug application for Intrinsa (a testosterone patch for hypoactive sexual desire disorder for women who had undergone surgical castration via bilateral oophorectomy). In spite of quality scientific data, Intrinsa was not approved. With this issue of IJIR, a new column, entitled, ‘perspective’ is provided to the readership. Perspective is an invited opinion or viewpoint that aims to advise and update the medical community on a pertinent or current topic in sexual medicine. Dr Richard Spark, a noted endocrinologist, presents the first of three invited ‘perspectives’ on Intrinsa and the FDA decision. Dr Spark has authored several manuscripts on the topic of FSD.

This is a preview of subscription content, access via your institution

Access options

Subscribe to this journal

Receive 8 print issues and online access

$259.00 per year

only $32.38 per issue

Buy this article

• Purchase on SpringerLink
• Instant access to full article PDF

Prices may be subject to local taxes which are calculated during checkout

Additional access options:

• Log in
• Learn about institutional subscriptions
• Read our FAQs
• Contact customer support

Similar content being viewed by others

Author information

Authors and Affiliations

1. Steroid Research Laboratory, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA
   R F Spark

Authors

1. R F Spark
   You can also search for this author inPubMed Google Scholar

Corresponding author

Correspondence toR F Spark.

Rights and permissions

About this article

Cite this article

Spark, R. Intrinsa fails to impress FDA advisory panel.Int J Impot Res 17, 283–284 (2005). https://doi.org/10.1038/sj.ijir.3901308

Download citation

• Received: 03 January 2005
• Accepted: 03 January 2005
• Published: 17 March 2005
• Issue Date: 01 May 2005
• DOI: https://doi.org/10.1038/sj.ijir.3901308

This article is cited by